Zacks Research Lifts Earnings Estimates for Globus Medical

Globus Medical, Inc. (NYSE:GMED) – Equities researchers at Zacks Research increased their Q3 2025 EPS estimates for Globus Medical in a research report issued on Thursday, December 12th. Zacks Research analyst R. Department now forecasts that the medical device company will earn $0.84 per share for the quarter, up from their previous forecast of $0.83. The consensus estimate for Globus Medical’s current full-year earnings is $2.97 per share. Zacks Research also issued estimates for Globus Medical’s Q2 2026 earnings at $0.98 EPS.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Tuesday, November 5th. The medical device company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.18. The company had revenue of $625.71 million for the quarter, compared to analysts’ expectations of $604.69 million. Globus Medical had a return on equity of 9.98% and a net margin of 3.69%. The firm’s revenue was up 63.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.57 earnings per share.

Several other analysts also recently issued reports on GMED. BTIG Research boosted their price objective on Globus Medical from $87.00 to $91.00 and gave the stock a “buy” rating in a report on Thursday. Roth Mkm restated a “buy” rating and set a $100.00 price target on shares of Globus Medical in a report on Wednesday, November 6th. Bank of America raised their price objective on shares of Globus Medical from $55.00 to $80.00 and gave the stock an “underperform” rating in a research note on Wednesday, November 6th. Morgan Stanley raised shares of Globus Medical from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $83.00 to $100.00 in a research note on Monday, December 2nd. Finally, StockNews.com cut Globus Medical from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $92.18.

Globus Medical Stock Down 0.4 %

Shares of Globus Medical stock opened at $82.42 on Monday. Globus Medical has a 12-month low of $49.14 and a 12-month high of $87.22. The firm has a market capitalization of $11.22 billion, a PE ratio of 123.01, a price-to-earnings-growth ratio of 1.99 and a beta of 1.19. The stock’s fifty day moving average is $78.81 and its 200-day moving average is $72.88.

Insider Activity at Globus Medical

In other news, CEO Daniel T. Scavilla sold 60,000 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $80.02, for a total transaction of $4,801,200.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Kelly Huller sold 2,500 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $87.00, for a total transaction of $217,500.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 97,500 shares of company stock valued at $7,674,950. Insiders own 18.54% of the company’s stock.

Institutional Trading of Globus Medical

Several large investors have recently made changes to their positions in GMED. Sanctuary Advisors LLC acquired a new stake in Globus Medical in the 2nd quarter worth approximately $611,000. Quest Partners LLC acquired a new stake in shares of Globus Medical in the third quarter worth $523,000. Intech Investment Management LLC boosted its holdings in shares of Globus Medical by 291.3% during the 3rd quarter. Intech Investment Management LLC now owns 20,530 shares of the medical device company’s stock worth $1,469,000 after buying an additional 15,283 shares during the period. Quantbot Technologies LP bought a new stake in shares of Globus Medical during the 3rd quarter worth $2,709,000. Finally, AXA S.A. raised its holdings in Globus Medical by 0.5% in the 2nd quarter. AXA S.A. now owns 1,478,242 shares of the medical device company’s stock worth $101,245,000 after acquiring an additional 7,443 shares during the period. Institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.